NASDAQ$OCUL
Ocular Therapeutix Inc · Q4 2019 earnings
Q4 2019 earnings · · Investor relations
Briefing
Ocular Therapeutix reported fourth quarter and year end 2019 financial results and provided a business update.
Ocular Therapeutix reported a strong end to 2019, with DEXTENZA net product revenue reaching $1.6 million, a 433% increase sequentially. The company is guiding first-quarter total net product revenue of $3.0 million to $3.2 million. Interim clinical data releases for OTX-TIC and OTX-TKI showed favorable safety profiles, tolerability, durability, and early biological activity.
- DEXTENZA net product revenue reached $1.6 million, a 433% sequential increase.
- The company is guiding first-quarter total net product revenue of $3.0 million to $3.2 million.
- Interim clinical data from Phase 1 programs OTX-TIC and OTX-TKI showed favorable results.
- OTX-CSI IND was filed, with a Phase 1 clinical trial expected to begin by mid-2020.
Headline financials
Revenue & EPS history
Ocular Therapeutix · Revenue · Quarterly
$2.26M
Revenue by segment
Ocular Therapeutix · $1.6M total across 1 segment · Q4 2019
- Product Revenue$1.6M—100.0%
Forward guidance
The company is guiding first-quarter total net product revenue of $3.0 million to $3.2 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2019
-2.3%
Avg return
Earnings day
+0.3%
Avg return
5 days after
+5.2%
Avg return
30 days after
33%
14 / 43 earnings
Positive
+24.0%
Q3 2016
Best reaction
-20.4%
Q3 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.7% | -1.2% | -10.0% | |
| Q3 2025 | -4.4% | -4.9% | +8.9% | |
| Q1 2025 | -12.4% | -19.8% | -4.8% | |
| Q4 2024 | +9.6% | +27.3% | +18.1% | |
| Q3 2024 | -13.6% | -15.8% | -18.0% | |
| Q2 2024 | +1.8% | +1.3% | +6.3% | |
| Q1 2024 | -0.9% | -2.4% | -10.3% | |
| Q4 2023 | -6.9% | -5.2% | -20.7% | |
| Q3 2023 | -10.7% | -23.7% | +34.8% | |
| Q2 2023 | -13.7% | -3.5% | -13.7% | |
| Q1 2023 | +4.8% | -0.6% | +18.6% | |
| Q4 2022 | -0.6% | -17.6% | -16.8% | |
| Q3 2022 | -9.7% | -6.6% | -20.0% | |
| Q2 2022 | -1.0% | +10.5% | +18.5% | |
| Q1 2022 | -4.3% | -5.5% | +12.4% | |
| Q4 2021 | -0.4% | -10.7% | -8.5% | |
| Q3 2021 | +9.5% | +0.0% | -2.9% | |
| Q2 2021 | +4.4% | +2.2% | +1.6% | |
| Q1 2021 | -5.1% | -9.4% | -13.3% | |
| Q4 2020 | +6.0% | -2.1% | -16.0% | |
| Q3 2020 | +6.6% | +11.1% | +68.8% | |
| Q2 2020 | +0.0% | -2.6% | -8.7% | |
| Q1 2020 | -1.7% | -4.8% | +9.0% | |
| Q4 2019 | -11.4% | +47.3% | +1.5% | |
| Q3 2019 | -5.5% | -4.4% | +38.2% | |
| Q2 2019 | -9.5% | -6.9% | -5.6% | |
| Q1 2019 | -4.6% | -1.6% | -9.0% | |
| Q4 2018 | -0.2% | +1.4% | +3.3% | |
| Q3 2018 | +8.0% | +1.0% | +11.1% | |
| Q2 2018 | +8.7% | +14.5% | +23.2% | |
| Q1 2018 | +0.3% | +6.4% | +7.7% | |
| Q4 2017 | -0.8% | +6.4% | +2.7% | |
| Q3 2017 | -13.7% | -12.1% | -34.4% | |
| Q2 2017 | -4.3% | -1.5% | +13.9% | |
| Q1 2017 | -11.3% | -9.9% | +20.9% | |
| Q4 2016 | -1.6% | +0.5% | -5.6% | |
| Q3 2016 | +24.0% | +42.9% | +77.3% | |
| Q2 2016 | -4.4% | +11.0% | +18.3% | |
| Q1 2016 | -8.0% | — | — | |
| Q4 2015 | +2.4% | — | — | |
| Q3 2015 | -20.4% | — | — | |
| Q2 2015 | -12.2% | — | — | |
| Q1 2015 | — | — | — | |
| Q3 2014 | +5.6% | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro